Ashford Capital Management Inc. Increases Holdings in Axon Enterprise, Inc $AXON

Ashford Capital Management Inc. lifted its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 6.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,955 shares of the biotechnology company’s stock after purchasing an additional 1,756 shares during the period. Axon Enterprise comprises approximately 1.6% of Ashford Capital Management Inc.’s investment portfolio, making the stock its 25th largest holding. Ashford Capital Management Inc.’s holdings in Axon Enterprise were worth $13,146,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in AXON. Vanguard Group Inc. grew its position in shares of Axon Enterprise by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock valued at $5,319,928,000 after acquiring an additional 53,060 shares during the period. Geode Capital Management LLC grew its holdings in Axon Enterprise by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock valued at $1,265,657,000 after purchasing an additional 35,544 shares during the period. Baillie Gifford & Co. grew its holdings in Axon Enterprise by 1,198.7% during the fourth quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock valued at $932,869,000 after purchasing an additional 1,516,099 shares during the period. Sands Capital Management LLC increased its position in Axon Enterprise by 11.6% in the fourth quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock worth $914,047,000 after buying an additional 167,095 shares during the last quarter. Finally, Wellington Management Group LLP raised its stake in shares of Axon Enterprise by 326.9% in the fourth quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock valued at $874,463,000 after buying an additional 1,179,038 shares during the period. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Wall Street Analysts Forecast Growth

AXON has been the subject of several recent research reports. The Goldman Sachs Group set a $535.00 price objective on Axon Enterprise in a report on Thursday, May 7th. TD Cowen reaffirmed a “buy” rating on shares of Axon Enterprise in a report on Wednesday, July 22nd. Royal Bank Of Canada reiterated an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, July 21st. Weiss Ratings raised shares of Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. Finally, JPMorgan Chase & Co. upped their price target on shares of Axon Enterprise from $750.00 to $755.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Fifteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Axon Enterprise presently has a consensus rating of “Moderate Buy” and a consensus price target of $725.25.

Insider Activity

In related news, insider Elizabeth Reid Coughlin sold 1,554 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $485.00, for a total value of $753,690.00. Following the sale, the insider directly owned 34,024 shares of the company’s stock, valued at $16,501,640. This trade represents a 4.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Caitlin Elizabeth Kalinowski sold 564 shares of Axon Enterprise stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $478.97, for a total transaction of $270,139.08. Following the sale, the director owned 3,632 shares of the company’s stock, valued at approximately $1,739,619.04. The trade was a 13.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 58,989 shares of company stock worth $30,527,983. Company insiders own 4.20% of the company’s stock.

Axon Enterprise Trading Up 4.6%

Shares of AXON stock opened at $525.48 on Tuesday. The company has a market capitalization of $42.35 billion, a PE ratio of 211.04, a price-to-earnings-growth ratio of 10.25 and a beta of 1.38. Axon Enterprise, Inc has a 52-week low of $339.01 and a 52-week high of $885.91. The business’s fifty day moving average is $485.78 and its 200 day moving average is $478.09. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, topping the consensus estimate of $1.60 by $0.01. The business had revenue of $807.35 million during the quarter, compared to analysts’ expectations of $778.90 million. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The firm’s revenue was up 33.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.47 earnings per share. On average, equities research analysts anticipate that Axon Enterprise, Inc will post 1.63 EPS for the current fiscal year.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.